A Quick Look at Today's Ratings for Pfizer(PFE.US), With a Forecast Between $30 to $36
Pfizer's Solid Fundamentals and Strategic Acquisitions Affirm Buy Rating Despite Oxbryta Setback
Pfizer's Investment Outlook: A Cautious Hold Amid Oxbryta Withdrawal and Mixed Acquisition Results
Jefferies Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $35
Jefferies Sticks to Its Buy Rating for Pfizer (PFE)
Jefferies Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $35
Pfizer (PFE) Receives a Buy From Jefferies
Pfizer Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
BMO Capital Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $36
Pfizer Analyst Ratings
Erste Group Initiates Pfizer(PFE.US) With Hold Rating
Berenberg Bank Reaffirms Their Hold Rating on Pfizer (PFE)
Pfizer Analyst Ratings
Citigroup Adjusts Price Target on Pfizer to $30 From $28, Maintains Neutral Rating
Pfizer Analyst Ratings
Daiwa Securities Upgrades Pfizer to Outperform From Neutral, Adjusts Price Target to $34 From $28
Truist Financial Maintains Pfizer(PFE.US) With Buy Rating
Moderna Stock Trading Lower On Dismal Guidance, Analysts Cuts Price Targets Noting Competitive Pressure From GSK, Pfizer
Argus Research Maintains Pfizer(PFE.US) With Hold Rating